Oceania Healthcare's (NZE:OCA, ASX:OCA) progress in care suits holds potential for near-term upside in free cash flow growth and re-rating, Jarden Research said in a Nov.25 note.
The healthcare services provider reported a loss of NZ$0.024 per share for the six months ended Sept. 30, compared with earnings of NZ$0.049 per share a year earlier.
Loss for the period was NZ$17.1 million, reversing the NZ$35.2 million profit a year earlier.
Jarden believes that Oceania Healthcare's faster realization of deferred management fees for care suites provides potential for nearer-term upside in free cash flow growth.
Faster realization of the fees, progress on further development execution, and inventory sell-down "could re-rate OCA sooner, taking into account other factors," Jarden added.
The investment firm maintained the company's neutral rating but raised its price target to NZ$0.83 from NZ$0.80.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.